drugset

drugset / Trial / NCT00245947

Study Evaluating ERB-041 in Active Crohn's Disease

NCT00245947 ↗

Phase 1 Completed 22 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluate the response of inflammatory serum markers to oral ERB-041 in subjects with inflammation associated with active Crohn's disease.

Timeline

Start: 2004-04
Primary completion: 2005-04
Completion: 2005-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PRINABEREL	Small molecule	—	Oral

Indications